Sanofi: Today's Tolebrutinib Setback Shouldn't Worry Shareholders - This Is Why

Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...

Sanofi flags second delay to FDA decision on multiple sclerosis drug, shares fall

Shares of French pharmaceutical group Sanofi fell 4% on Monday after it flagged another delay to a U.S. regulatory decision ...
STAT

Pharmalittle: We’re reading about FDA approval for a novel antibiotic, setbacks at Sanofi, and much more

Sanofi flagged a second delay to an FDA decision for its experimental multiple sclerosis drug and reported disappointing ...
Oneindia

Drug Approvals in 2025 Signal Major Shifts in Chronic Care and Infection Control

In 2025, drug approvals widen treatment options for chronic diseases, infections and pain, including Ozempic kidney ...
newscase

Operational Gains and Clinical Catalysts: Apogee Therapeutics Strengthens Its Foundation

Biotechnology firm Apogee Therapeutics has reported significant operational improvements following the integration of ZAGENO's procurement platform into its ...